Details

Autor(en) / Beteiligte

• Schmaltz, Carolina Arana Stanis
• Demitto, Fernanda de Oliveira
• Sant'Anna, Flavia Marinho
• Rolla, Valeria Cavalcanti

Titel

Tuberculosis-HIV treatment with rifampicin or rifabutin: are the outcomes different?

Ist Teil von

• Memórias do Instituto Oswaldo Cruz, 2019-01, Vol.114, p.e180420

Ort / Verlag

Brazil: Instituto Oswaldo Cruz, Ministério da Saúde

Erscheinungsjahr

2019

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Rifamycins are a group of antibiotics mainly used in the treatment of tuberculosis (TB), however they interact with antiretroviral therapy (ART). Rifabutin allows more regimens options for concomitant imunodeficiency virus (HIV) treatment compared to rifampicin. Compare the outcomes of TB-HIV co-infected patients who used rifampicin or rifabutin. We analysed data from a prospective cohort study at National Institute of Infectious Diseases Evandro Chagas, Rio de Janeiro (RJ), Brazil. Patients who were treated for TB and HIV with rifampicin or rifabutin, from February 2011 to September 2016 were included. There were 130 TB-HIV patients, of whom 102 were treated with rifampicin and 28 with rifabutin. All patients in the rifabutin-treated group and 55% of the rifampicin-treated group patients were ART-experienced. Patients treated with rifampicin had similar abandon and cure rates, interruptions in treatment due to adverse reactions, immune reconstitution inflammatory syndrome and a similar mortality rate as those treated with rifabutin. However, rifampicin-treated patients had higher CD4 counts and more frequently undetectable HIV viral load by the end of treatment (67% versus 18%, p < 0.001) compared to rifabutin-treated patients, even when only ART-experienced patients were evaluated (66,6% versus 36,3%, p = 0.039). Patients who used rifabutin had worst immune and virological control. This group had more ART-experienced patients. New and simpler regimens are needed for patients who do not respond to previous antiretroviral therapies.